An integrated approach to biologics R&D
Incyte develops a wide range of therapeutics, primarily for oncology. Benchling supports their antibody discovery group.
Challenges
| Lack of a central informatics solution | Incyte’s antibody discovery group was starting from the ground-up and knew it would be pivotal to deploy a world-class informatics system as soon as possible. |
|---|---|
| Difficulty in tracking experimental results and progress | With a growing team and fluid processes, the antibody discovery group needed a flexible system, or else their data would be unreliable and difficult to track. |
| Collaborating across intercontinental sites without a shared system | Being able to work with external collaborators (including international collaborators) was a must. |
Outcomes
| Tracking constructs and components | Benchling’s ability to automatically identify and register scFvs’ components makes it easy to track constructs. |
|---|---|
| Secure data for collaborations | With Benchling’s rich data permissions, Incyte can extend the system to its external collaborators, streamlining secure data transfer. |
| Data clarity from the start | Since the start of their operations, the antibody discovery group has gotten visibility into their key processes. |
